Sporozoite immunization of human volunteers under chemoprophylaxis induces functional antibodies against pre-erythrocytic stages of Plasmodium falciparum

Malaria Journal

Volumn 13, Issue 1, 2014, Pages

  Behet, Marije C ^a   Foquet, Lander ^b   Van Gemert, Geert Jan ^a   Bijker, Else M ^a   Meuleman, Philip ^b   Leroux Roels, Geert ^b   Hermsen, Cornelus C ^a   Scholzen, Anja ^a   Sauerwein, Robert W ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

CHMI; CPS; Human liver uPA SCID mouse model; Immunization; Inhibitory antibodies; Liver stage; Malaria; Plasmodium falciparum; Sporozoites

Indexed keywords

ANTIBODY; MALARIA VACCINE;

ANTIBODY RESPONSE; ARTICLE; CELL INTERACTION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; HUMAN; IMMUNIZATION; IN VITRO STUDY; LIVER; LIVER CELL; NONHUMAN; PASSIVE IMMUNIZATION; PLASMODIUM FALCIPARUM; SPOROZOITE;

ADULT; ANIMALS; ANOPHELES; ANTIBODIES, PROTOZOAN; ANTIMALARIALS; CHLOROQUINE; ERYTHROCYTES; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; SPOROZOITES; YOUNG ADULT;

EID: 84899474267     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-13-136     Document Type: Article

References (78)

1. Malaria sporozoites leave behind trails of circumsporozoite protein during gliding motility. Stewart MJ, Vanderberg JP, J Protozool 1988 35 389 393 10.1111/j.1550-7408.1988.tb04115.x 3054075
2. Migration of Plasmodium sporozoites through cells before infection. Mota MM, Pradel G, Vanderberg JP, Hafalla JC, Frevert U, Nussenzweig RS, Nussenzweig V, Rodriguez A, Science 2001 291 141 144 10.1126/science.291.5501.141 11141568
3. Host cell traversal is important for progression of the malaria parasite through the dermis to the liver. Amino R, Giovannini D, Thiberge S, Gueirard P, Boisson B, Dubremetz JF, Prevost MC, Ishino T, Yuda M, Menard R, Cell Host Microbe 2008 3 88 96 10.1016/j.chom.2007.12.007 18312843
4. Plasmodium berghei sporozoite invasion is blocked in vitro by sporozoite-immobilizing antibodies. Stewart MJ, Nawrot RJ, Schulman S, Vanderberg JP, Infect Immun 1986 51 859 864 3512436
5. Intracellular parasite invasion strategies. Sibley LD, Science 2004 304 248 253 10.1126/science.1094717 15073368
6. Cell-passage activity is required for the malarial parasite to cross the liver sinusoidal cell layer. Ishino T, Yano K, Chinzei Y, Yuda M, PLoS Biol 2004 2 4 10.1371/journal.pbio.0020004 14737184
7. Role of host cell traversal by the malaria sporozoite during liver infection. Tavares J, Formaglio P, Thiberge S, Mordelet E, Van Rooijen N, Medvinsky A, Menard R, Amino R, J Exp Med 2013 210 905 915 10.1084/jem.20121130 23610126
8. Looking under the skin: the first steps in malarial infection and immunity. Menard R, Tavares J, Cockburn I, Markus M, Zavala F, Amino R, Nat Rev Microbiol 2013 11 701 712 10.1038/nrmicro3111 24037451
9. The silent path to thousands of merozoites: the Plasmodium liver stage. Prudencio M, Rodriguez A, Mota MM, Nat Rev Microbiol 2006 4 849 856 10.1038/nrmicro1529 17041632
10. Acquired immunity to malaria. Doolan DL, Dobano C, Baird JK, Clin Microbiol Rev 2009 22 13 36 10.1128/CMR.00025-08 19136431
11. Gamma-globulin and acquired immunity to human malaria. Cohen S, McGregor IA, Carrington S, Nature 1961 192 733 737 10.1038/192733a0 13880318
12. Treatment of East African P. falciparum malaria with West African human gamma-globulin. McGregor IA, Carrington SP, Cohen S, Trans R Soc Trop Med Hyg 1963 57 170 175 10.1016/0035-9203(63)90058-0
13. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Sabchareon A, Burnouf T, Ouattara D, Attanath P, Bouharoun-Tayoun H, Chantavanich P, Foucault C, Chongsuphajaisiddhi T, Druilhe P, Am J Trop Med Hyg 1991 45 297 308 1928564
14. Demonstration of passive immunity in experimental monkey malaria. Coggeshall LT, Kumm HW, J Exp Med 1937 66 177 190 10.1084/jem.66.2.177 19870655
15. Transplacental passage of Plasmodium berghei and passive transfer of immunity in rats and mice. Bruce-Chwatt LJ, Gibson FD, Trans R Soc Trop Med Hyg 1956 50 47 53 10.1016/0035-9203(56)90007-4 13299350
16. Humoral immunity in rodent malaria. II. Inhibition of parasitemia by serum antibody. Diggs CL, Osler AG, J Immunol 1969 102 298 305 4885245
17. Development of sporozoite vaccines. Nussenzweig RS, Nussenzweig V, Philos Trans R Soc Lond B Biol Sci 1984 307 117 128 10.1098/rstb.1984.0113 6084251
18. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS, S Malaria Vaccine Evaluation Group. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, Wellde BT, Garcon N, Krzych U, Marchand M, N Engl J Med 1997 336 86 91 10.1056/NEJM199701093360202 8988885
19. Rts SMVEG: A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS, S/AS02A in malaria-naive adults. Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG Jr, Hall T, Wellde BT, White K, Sun P, Schwenk R, Krzych U, Delchambre M, Voss G, Dubois MC, Gasser RA Jr, Dowler MG, O'Brien M, Wittes J, Wirtz R, Cohen J, Ballou WR, Vaccine 2007 25 5359 5366 10.1016/j.vaccine.2007.05.005 17574311
20. Rts SMVEG: Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS, S/AS02 in malaria-naive adults at the Walter Reed Army Institute of Research. Kester KE, Cummings JF, Ockenhouse CF, Nielsen R, Hall BT, Gordon DM, Schwenk RJ, Krzych U, Holland CA, Richmond G, Dowler MG, Williams J, Wirtz RA, Tornieporth N, Vigneron L, Delchambre M, Demoitie MA, Ballou WR, Cohen J, Heppner DG Jr, Vaccine 2008 26 2191 2202 10.1016/j.vaccine.2008.02.048 18387719
21. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS, S/AS01B and RTS, S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris P, Schwenk R, Nielsen RA, Debebe Z, Pinelis E, Juompan L, Williams J, Dowler M, Stewart VA, Wirtz RA, Dubois MC, Lievens M, Cohen J, Ballou WR, Heppner DG Jr, Rts SVEG, J Infect Dis 2009 200 337 346 10.1086/600120 19569965
22. Long-term efficacy and immune responses following immunization with the RTS, S malaria vaccine. Stoute JA, Kester KE, Krzych U, Wellde BT, Hall T, White K, Glenn G, Ockenhouse CF, Garcon N, Schwenk R, Lanar DE, Sun P, Momin P, Wirtz RA, Golenda C, Slaoui M, Wortmann G, Holland C, Dowler M, Cohen J, Ballou WR, J Infect Dis 1998 178 1139 1144 10.1086/515657 9806046
23. The RTS, S malaria vaccine. Casares S, Brumeanu TD, Richie TL, Vaccine 2010 28 4880 4894 10.1016/j.vaccine.2010.05.033 20553771
24. A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants. Rts SCTP, Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG, Kabwende AL, Adegnika AA, Mordmuller B, Issifou S, Kremsner PG, Sacarlal J, Aide P, Lanaspa M, Aponte JJ, Machevo S, Acacio S, Bulo H, Sigauque B, Macete E, Alonso P, Abdulla S, Salim N, Minja R, Mpina M, Ahmed S, Ali AM, Mtoro AT, Hamad AS, Mutani P, et al. N Engl J Med 2012 367 2284 2295 23136909
25. The relationship between RTS, S vaccine-induced antibodies, CD4(+) T cell responses and protection against Plasmodium falciparum infection. White MT, Bejon P, Olotu A, Griffin JT, Riley EM, Kester KE, Ockenhouse CF, Ghani AC, PLoS One 2013 8 61395 10.1371/journal.pone.0061395 23613845
26. Four-year efficacy of RTS, S/AS01E and its interaction with malaria exposure. Olotu A, Fegan G, Wambua J, Nyangweso G, Awuondo KO, Leach A, Lievens M, Leboulleux D, Njuguna P, Peshu N, Marsh K, Bejon P, N Engl J Med 2013 368 1111 1120 10.1056/NEJMoa1207564 23514288
27. Expression of thrombospondin-related anonymous protein in Plasmodium falciparum sporozoites. Cowan G, Krishna S, Crisanti A, Robson K, Lancet 1992 339 1412 1413 10.1016/0140-6736(92)91229-2 1350818
28. Characterization of Plasmodium falciparum sporozoite surface protein 2. Rogers WO, Malik A, Mellouk S, Nakamura K, Rogers MD, Szarfman A, Gordon DM, Nussler AK, Aikawa M, Hoffman SL, Proc Natl Acad Sci U S A 1992 89 9176 9180 10.1073/pnas.89.19.9176 1409621
29. Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein. Khusmith S, Charoenvit Y, Kumar S, Sedegah M, Beaudoin RL, Hoffman SL, Science 1991 252 715 718 10.1126/science.1827210 1827210
30. Safety and immunogenicity of rts, s + trap malaria vaccine, formulated in the AS02A adjuvant system, in infant rhesus monkeys. Walsh DS, Pichyangkul S, Gettayacamin M, Tongtawe P, Siegrist CA, Hansukjariya P, Kester KE, Holland CA, Voss G, Cohen J, Stewart AV, Miller RS, Ballou WR, Heppner DG Jr, Am J Trop Med Hyg 2004 70 499 509 15155981
31. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection. Cummings JF, Spring MD, Schwenk RJ, Ockenhouse CF, Kester KE, Polhemus ME, Walsh DS, Yoon IK, Prosperi C, Juompan LY, Lanar DE, Krzych U, Hall BT, Ware LA, Stewart VA, Williams J, Dowler M, Nielsen RK, Hillier CJ, Giersing BK, Dubovsky F, Malkin E, Tucker K, Dubois MC, Cohen JD, Ballou WR, Heppner DG Jr, Vaccine 2010 28 5135 5144 10.1016/j.vaccine.2009.08.046 19737527
32. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nussenzweig RS, Vanderberg J, Most H, Orton C, Nature 1967 216 160 162 10.1038/216160a0 6057225
33. Preliminary studies on vaccination of rhesus monkeys with irradiated sporozoites of Plasmodium knowlesi and characterization of surface antigens of these parasites. Gwadz RW, Cochrane AH, Nussenzweig V, Nussenzweig RS, Bull World Health Organ 1979 57 Suppl 1 165 173 120766
34. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, Doolan DL, Sacci J, de la Vega P, Dowler M, Paul C, Gordon DM, Stoute JA, Church LW, Sedegah M, Heppner DG, Ballou WR, Richie TL, J Infect Dis 2002 185 1155 1164 10.1086/339409 11930326
35. Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Schofield L, Villaquiran J, Ferreira A, Schellekens H, Nussenzweig R, Nussenzweig V, Nature 1987 330 664 666 10.1038/330664a0 3120015
36. Reduced Plasmodium berghei sporozoite liver load associates with low protective efficacy after intradermal immunization. Nganou-Makamdop K, Ploemen I, Behet M, Van Gemert GJ, Hermsen C, Roestenberg M, Sauerwein RW, Parasite Immunol 2012 34 562 569 10.1111/pim.12000.x 23171040
37. Inhibition of entry of Plasmodium falciparum and P. vivax sporozoites into cultured cells; an in vitro assay of protective antibodies. Hollingdale MR, Nardin EH, Tharavanij S, Schwartz AL, Nussenzweig RS, J Immunol 1984 132 909 913 6317752
38. Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Egan JE, Hoffman SL, Haynes JD, Sadoff JC, Schneider I, Grau GE, Hollingdale MR, Ballou WR, Gordon DM, Am J Trop Med Hyg 1993 49 166 173 8357078
39. Successful immunization of humans with irradiated malaria sporozoites: humoral and cellular responses of the protected individuals. Herrington D, Davis J, Nardin E, Beier M, Cortese J, Eddy H, Losonsky G, Hollingdale M, Sztein M, Levine M, Nussenzweig R, Clyde DF, Edelman R, Am J Trop Med Hyg 1991 45 539 547 1951863
40. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, Gordon IJ, Holman LA, James ER, Billingsley PF, Gunasekera A, Richman A, Chakravarty S, Manoj A, Velmurugan S, Li M, Ruben AJ, Li T, Eappen AG, Stafford RE, Plummer SH, Hendel CS, Novik L, Costner PJ, Mendoza FH, Saunders JG, Nason MC, Richardson JH, Murphy J, Davidson SA, Richie TL, et al. Science 2013 341 1359 1365 10.1126/science.1241800 23929949
41. Model for in vivo assessment of humoral protection against malaria sporozoite challenge by passive transfer of monoclonal antibodies and immune serum. Sack BK, Miller JL, Vaughan AM, Douglass A, Kaushansky A, Mikolajczak S, Coppi A, Gonzalez-Aseguinolaza G, Tsuji M, Zavala F, Sinnis P, Kappe SH, Infect Immun 2014 82 808 817 10.1128/IAI.01249-13 24478094
42. First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers. Spring M, Murphy J, Nielsen R, Dowler M, Bennett JW, Zarling S, Williams J, de la Vega P, Ware L, Komisar J, Polhemus M, Richie TL, Epstein J, Tamminga C, Chuang I, Richie N, O'Neil M, Heppner DG, Healer J, O'Neill M, Smithers H, Finney OC, Mikolajczak SA, Wang R, Cowman A, Ockenhouse C, Krzych U, Kappe SH, Vaccine 2013 31 4975 4983 10.1016/j.vaccine.2013.08.007 24029408
43. Immunization with genetically attenuated P. falciparum parasites induces long-lived antibodies that efficiently block hepatocyte invasion by sporozoites. Finney OC, Keitany GJ, Smithers H, Kappe S, Wang R, Vaccine 2014 doi: 10.1016/j.vaccine.2014.02.055. [Epub ahead of print]
44. Protection against a malaria challenge by sporozoite inoculation. Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, Van Gemert GJ, van de Vegte-Bolmer M, Van Schaijk B, Teelen K, Arens T, Spaarman L, De Mast Q, Roeffen W, Snounou G, Renia L, van der Ven A, Hermsen CC, Sauerwein R, N Engl J Med 2009 361 468 477 10.1056/NEJMoa0805832 19641203
45. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Roestenberg M, Teirlinck AC, McCall MB, Teelen K, Makamdop KN, Wiersma J, Arens T, Beckers P, Van Gemert G, van de Vegte-Bolmer M, van der Ven AJ, Luty AJ, Hermsen CC, Sauerwein RW, Lancet 2011 377 1770 1776 10.1016/S0140-6736(11)60360-7 21514658
46. Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity. Bijker EM, Bastiaens GJ, Teirlinck AC, Van Gemert GJ, Graumans W, van de Vegte-Bolmer M, Siebelink-Stoter R, Arens T, Teelen K, Nahrendorf W, Remarque EJ, Roeffen W, Jansens A, Zimmerman D, Vos M, Van Schaijk BC, Wiersma J, van der Ven AJ, De Mast Q, Van Lieshout L, Verweij JJ, Hermsen CC, Scholzen A, Sauerwein RW, Proc Natl Acad Sci U S A 2013 110 7862 7867 10.1073/pnas.1220360110 23599283
47. Longevity and composition of cellular immune responses following experimental Plasmodium falciparum malaria infection in humans. Teirlinck AC, McCall MB, Roestenberg M, Scholzen A, Woestenenk R, De Mast Q, van der Ven AJ, Hermsen CC, Luty AJ, Sauerwein RW, PLoS Pathog 2011 7 1002389 10.1371/journal.ppat.1002389 22144890
48. Pre-erythrocytic antibody profiles induced by controlled human malaria infections in healthy volunteers under chloroquine prophylaxis. Felgner PL, Roestenberg M, Liang L, Hung C, Jain A, Pablo J, Nakajima-Sasaki R, Molina D, Teelen K, Hermsen CC, Sauerwein R, Sci Rep 2013 3 3549 24351974
49. Complete in vitro maturation of Plasmodium falciparum gametocytes. Ifediba T, Vanderberg JP, Nature 1981 294 364 366 10.1038/294364a0 7031476
50. Cultivation of fertile Plasmodium falciparum gametocytes in semi-automated systems. 1. Static cultures. Ponnudurai T, Lensen AH, Leeuwenberg AD, Meuwissen JH, Trans R Soc Trop Med Hyg 1982 76 812 818 10.1016/0035- 9203(82)90116-X 6761910
51. Synchronization of Plasmodium falciparum gametocytes using an automated suspension culture system. Ponnudurai T, Lensen AH, Meis JF, Meuwissen JH, Parasitology 1986 93 Pt 2 263 274 3537921
52. Infectivity of cultured Plasmodium falciparum gametocytes to mosquitoes. Ponnudurai T, Lensen AH, Van Gemert GJ, Bensink MP, Bolmer M, Meuwissen JH, Parasitology 1989 98 Pt 2 165 173 2668861
53. Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax. Nardin EH, Nussenzweig V, Nussenzweig RS, Collins WE, Harinasuta KT, Tapchaisri P, Chomcharn Y, J Exp Med 1982 156 20 30 10.1084/jem.156.1.20 7045272
54. Dissecting in vitro host cell infection by Plasmodium sporozoites using flow cytometry. Prudencio M, Rodrigues CD, Ataide R, Mota MM, Cell Microbiol 2008 10 218 224 17697130
55. Establishment of a human hepatocyte line that supports in vitro development of the exo-erythrocytic stages of the malaria parasites Plasmodium falciparum and P. vivax. Sattabongkot J, Yimamnuaychoke N, Leelaudomlipi S, Rasameesoraj M, Jenwithisuk R, Coleman RE, Udomsangpetch R, Cui L, Brewer TG, Am J Trop Med Hyg 2006 74 708 715 16687667
56. Effects of cytochalasin, phalloidin, and pH on the elongation of actin filaments. Sampath P, Pollard TD, Biochemistry 1991 30 1973 1980 10.1021/bi00221a034 1899622
57. Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Meuleman P, Libbrecht L, De Vos R, de Hemptinne B, Gevaert K, Vandekerckhove J, Roskams T, Leroux-Roels G, Hepatology 2005 41 847 856 10.1002/hep.20657 15791625
58. Molecular detection and quantification of Plasmodium falciparum-infected human hepatocytes in chimeric immune-deficient mice. Foquet L, Hermsen CC, Van Gemert GJ, Libbrecht L, Sauerwein R, Meuleman P, Leroux-Roels G, Malar J 2013 12 430 10.1186/1475-2875-12-430 24267791
59. Comparison of Plasmodium berghei challenge models for the evaluation of pre-erythrocytic malaria vaccines and their effect on perceived vaccine efficacy. Leitner WW, Bergmann-Leitner ES, Angov E, Malar J 2010 9 145 10.1186/1475-2875-9-145 20507620
60. Life cycle and patterns of development of Plasmodium berghei in normal and experimental hosts. Yoeli M, Upmanis RS, Vanderberg J, Most H, Mil Med 1966 131 Suppl 900 914 4380325
61. Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection. Foquet L, Hermsen CC, Van Gemert GJ, Van Braeckel E, Weening KE, Sauerwein R, Meuleman P, Leroux-Roels G, J Clin Invest 2013 124 140 144
62. Detection of Plasmodium falciparum malaria parasites in vivo by real-time quantitative PCR. Hermsen CC, Telgt DS, Linders EH, van de Locht LA, Eling WM, Mensink EJ, Sauerwein RW, Mol Biochem Parasitol 2001 118 247 251 10.1016/S0166-6851(01)00379-6 11738714
63. Real-time PCR-based assay to quantify the relative amount of human and mouse tissue present in tumor xenografts. Alcoser SY, Kimmel DJ, Borgel SD, Carter JP, Dougherty KM, Hollingshead MG, BMC Biotechnol 2011 11 124 10.1186/1472-6750-11-124 22176647
64. Intravital microscopy demonstrating antibody-mediated immobilisation of Plasmodium berghei sporozoites injected into skin by mosquitoes. Vanderberg JP, Frevert U, Int J Parasitol 2004 34 991 996 10.1016/j.ijpara.2004.05.005 15313126
65. Assessment of antibody protection against malaria sporozoites must be done by mosquito injection of sporozoites. Vanderberg J, Mueller AK, Heiss K, Goetz K, Matuschewski K, Deckert M, Schluter D, Am J Pathol 2007 171 1405 1406 author reply 1406 10.2353/ajpath.2007.070661 17823294
66. Kinetics of mosquito-injected Plasmodium sporozoites in mice: fewer sporozoites are injected into sporozoite-immunized mice. Kebaier C, Voza T, Vanderberg J, PLoS Pathog 2009 5 1000399 10.1371/journal.ppat.1000399 19390607
67. Development of a quantitative flow cytometry-based assay to assess infection by Plasmodium falciparum sporozoites. Kaushansky A, Rezakhani N, Mann H, Kappe SH, Mol Biochem Parasitol 2012 183 100 103 10.1016/j.molbiopara.2012. 01.006 22342965
68. Genetically attenuated, P36p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells. Van Dijk MR, Douradinha B, Franke-Fayard B, Heussler V, Van Dooren MW, Van Schaijk B, Van Gemert GJ, Sauerwein RW, Mota MM, Waters AP, Janse CJ, Proc Natl Acad Sci U S A 2005 102 12194 12199 10.1073/pnas.0500925102 16103357
69. Gene disruption of Plasmodium falciparum p52 results in attenuation of malaria liver stage development in cultured primary human hepatocytes. Van Schaijk BC, Janse CJ, Van Gemert GJ, Van Dijk MR, Gego A, Franetich JF, van de Vegte-Bolmer M, Yalaoui S, Silvie O, Hoffman SL, Waters AP, Mazier D, Sauerwein RW, Khan SM, PLoS One 2008 3 3549 10.1371/journal.pone.0003549 18958160
70. Activity of human volunteer sera to candidate Plasmodium falciparum circumsporozoite protein vaccines in the inhibition of sporozoite invasion assay of human hepatoma cells and hepatocytes. Hollingdale MR, Appiah A, Leland P, do Rosario VE, Mazier D, Pied S, Herrington DA, Chulay JD, Ballou WR, Derks T, Hiem Yap S, Beaudoin RL, Verhave JP, Trans R Soc Trop Med Hyg 1990 84 325 329 10.1016/0035-9203(90)90303-V 2175464
71. Migration through host cells activates Plasmodium sporozoites for infection. Mota MM, Hafalla JC, Rodriguez A, Nat Med 2002 8 1318 1322 10.1038/nm785 12379848
72. A malaria heat-shock-like determinant expressed on the infected hepatocyte surface is the target of antibody-dependent cell-mediated cytotoxic mechanisms by nonparenchymal liver cells. Renia L, Mattei D, Goma J, Pied S, Dubois P, Miltgen F, Nussler A, Matile H, Menegaux F, Gentilini M, Mazier D, Eur J Immunol 1990 20 1445 1449 10.1002/eji.1830200706 2201546
73. Hepatic phase of malaria is the target of cellular mechanisms induced by the previous and the subsequent stages. A crucial role for liver nonparenchymal cells. Mazier D, Renia L, Nussler A, Pied S, Marussig M, Goma J, Grillot D, Miltgen F, Drapier JC, Corradin G, Del Giudice G, Grau GE, Immunol Lett 1990 25 65 70 10.1016/0165-2478(90)90093-6 1980910
74. Functional status of cells from lymphoid and myeloid tissues in mice with severe combined immunodeficiency disease. Dorshkind K, Keller GM, Phillips RA, Miller RG, Bosma GC, O'Toole M, Bosma MJ, J Immunol 1984 132 1804 1808 6607948
75. Natural killer (NK) cells are present in mice with severe combined immunodeficiency (scid). Dorshkind K, Pollack SB, Bosma MJ, Phillips RA, J Immunol 1985 134 3798 3801 3989296
76. The mechanisms of antibody-dependent killing mediated by lymphoid and myeloid cells are distinct based on different divalent cation requirements. Graziano RF, Erbe DV, Fanger MW, J Immunol 1989 143 3894 3900 2574205
77. Profiling humoral immune responses to P. falciparum infection with protein microarrays. Doolan DL, Mu Y, Unal B, Sundaresh S, Hirst S, Valdez C, Randall A, Molina D, Liang X, Freilich DA, Oloo JA, Blair PL, Aguiar JC, Baldi P, Davies DH, Felgner PL, Proteomics 2008 8 4680 4694 10.1002/pmic.200800194 18937256
78. Sterile protective immunity to malaria is associated with a panel of novel P. falciparum antigens. Trieu A, Kayala MA, Burk C, Molina DM, Freilich DA, Richie TL, Baldi P, Felgner PL, Doolan DL, Mol Cell Proteomics 2011 10 111 007948 10.1074/mcp.M111.007948 21628511